Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q34659834)
Watch
English
Coagulation factor concentrates: past, present, and future.
scientific article
In more languages
default for all languages
No label defined
No description defined
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed publication ID
17679021
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17679021%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 January 2020
review article
1 reference
stated in
Europe PubMed Central
title
Coagulation factor concentrates: past, present, and future
(English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
17679021
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17679021%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 January 2020
author
Claude Negrier
series ordinal
2
1 reference
stated in
Europe PubMed Central
PubMed publication ID
17679021
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17679021%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 January 2020
Valerie Chamouard
0 references
author name string
Nigel S Key
series ordinal
1
1 reference
stated in
Europe PubMed Central
PubMed publication ID
17679021
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17679021%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 January 2020
language of work or name
English
0 references
publication date
1 August 2007
1 reference
stated in
Europe PubMed Central
PubMed publication ID
17679021
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17679021%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 January 2020
published in
The Lancet
1 reference
stated in
Europe PubMed Central
PubMed publication ID
17679021
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17679021%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 January 2020
volume
370
1 reference
stated in
Europe PubMed Central
PubMed publication ID
17679021
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17679021%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 January 2020
issue
9585
1 reference
stated in
Europe PubMed Central
PubMed publication ID
17679021
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17679021%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 January 2020
page(s)
439-448
1 reference
stated in
Europe PubMed Central
PubMed publication ID
17679021
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17679021%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 January 2020
cites work
Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Estimating the cumulative incidence of HIV infection among persons with haemophilia in the United States of America
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Contamination of coagulation factor concentrates with human parvovirus B19 genotype 1 and 2
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Parvovirus B19 transmission by heat-treated clotting factor concentrates
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Variant Creutzfeldt-Jakob disease transmission by plasma products: assessing and communicating risk in an era of scientific uncertainty.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical perspectives of emerging pathogens in bleeding disorders.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Haemophilias A and B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Haemophilia prophylaxis in young patients--a long-term follow-up
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Human recombinant DNA-derived antihemophilic factor in the treatment of previously untreated patients with hemophilia A: final report on a hallmark clinical investigation
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Full-length sucrose-formulated recombinant factor VIII for treatment of previously untreated or minimally treated young children with severe haemophilia A: results of an international clinical investigation
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical use of a new glycine-precipitated antihemophilic fraction
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A new high-potency glycine-precipitated antihemophilic factor (AHF) concentrate. Treatment of classical hemophilia and hemophilia with inhibitors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hepatitis and Clotting-Factor Concentrates
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Asymptomatic liver disease in haemophiliacs
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Hepatitis C antibody and chronic liver disease in haemophilia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Generalized lymphadenopathy and T cell abnormalities in hemophilia A
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
HIV infection in haemophilia--a European cohort
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Characterization of the human factor VIII gene
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Molecular cloning of a cDNA encoding human antihaemophilic factor
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Managing the risk of transmission of variant Creutzfeldt Jakob disease by blood products
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prophylaxis for severe haemophilia: clinical and economical issues
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prothrombal: a new concentrate of human prothrombin complex for clinical use.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Small scale preparation and clinical use of factor IX-prothrombin complex
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Factor VII and activated-factor-VII content of prothrombin complex concentrates. The PCC Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thrombogenic materials in prothrombin complex concentrates
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Myocardial necrosis after therapy with prothrombin-complex concentrate
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thrombogenicity of prothrombin complex concentrates
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identification of prothrombin as a major thrombogenic agent in prothrombin complex concentrates
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prothrombin overload causes thromboembolic complications in prothrombin complex concentrates: in vitro and in vivo evidence
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Current therapy for rare factor deficiencies
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Massive blood transfusion in the elective surgical setting.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Correction of abnormal coagulation in chronic liver disease by combined use of fresh-frozen plasma and prothrombin complex concentrates
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy and safety of a prothrombin complex concentrate with two virus-inactivation steps in patients with severe liver damage
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Molecular cloning of the gene for human anti-haemophilic factor IX.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The gene structure of human anti-haemophilic factor IX.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Factor Xa and prothrombin: mechanism of action of FEIBA.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. FEIBA Study Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thrombelastography
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Views on methods for monitoring recombinant factor VIIa in inhibitor patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Inhibitors in congenital coagulation disorders
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Therapeutic decision-making in inhibitor patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment of von Willebrand's Disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
How I treat patients with von Willebrand disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Incidence of bleeding symptoms in 100 patients with inherited afibrinogenemia or hypofibrinogenemia
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy and tolerability of a pasteurised human fibrinogen concentrate in patients with congenital fibrinogen deficiency
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Spontaneous intracranial bleeding in two patients with congenital afibrinogenaemia and the role of replacement therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
[High dose fibrinogen administration for acute therapy of coagulopathy during massive perioperative transfusion]
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Factor VII Deficiency
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Recombinant factor VIIa (Eptacog Alfa): a review of its use in congenital or acquired haemophilia and other congenital bleeding disorders
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The use of recombinant factor VIIa in the treatment of bleeding disorders.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Congenital factor VII deficiency: therapy with recombinant activated factor VII -- a critical appraisal
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Inheritance and bleeding in factor XI deficiency
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
United States' factor XI-deficiency patients need a safer treatment
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Factor XIIIA and clot strength after cardiopulmonary bypass
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Factor XIII replacement in stem cell transplant (SCT) recipients with severe graft-versus-host disease of the bowel: report of an initial experience
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Factor XIII in chronic inflammatory bowel diseases
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Recombinant activated factor VII for acute intracerebral hemorrhage.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Safety and efficacy of a single bolus administration of recombinant factor VIIa in liver transplantation due to chronic liver disease.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy and safety of repeated perioperative doses of recombinant factor VIIa in liver transplantation.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double-blind, randomized, placebo-controlled trial.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Thromboembolic adverse events after use of recombinant human coagulation factor VIIa
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Off-label reports of new biologics: exciting new therapy or dubious research? Examples from recombinant activated factor VII.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treating warfarin-related intracerebral hemorrhage: is fresh frozen plasma enough?
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Reversal of warfarin-induced excessive anticoagulation with recombinant human factor VIIa concentrate
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Beriplex P/N reverses severe warfarin-induced overanticoagulation immediately and completely in patients presenting with major bleeding
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Guidelines on oral anticoagulation (warfarin): third edition--2005 update
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
New anticoagulants
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Recombinant factor VIIa reverses the anticoagulant effect of the long-acting pentasaccharide idraparinux in healthy volunteers
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Reversal of a potent investigational anticoagulant: idraparinux with recombinant factor VIIa
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A placebo-controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Clinical management of protein C deficiency
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment of purpura fulminans in meningococcemia with protein C concentrate
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Efficacy and safety of recombinant human activated protein C for severe sepsis
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The promise and challenges of bioengineered recombinant clotting factors
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Neutralization of antifactor VIII inhibitors by recombinant porcine factor VIII.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Treatment for all: a vision for the future
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prophylactic effect of recombinant factor VIIa in factor VII deficient patients.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Prophylaxis in rare coagulation disorders -- factor XIII deficiency
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Immunoadsorption for coagulation factor inhibitors: a retrospective critical appraisal of 10 consecutive cases from a single institution
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2807%2961199-4
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0140-6736(07)61199-4
1 reference
stated in
Europe PubMed Central
PubMed publication ID
17679021
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17679021%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 January 2020
PubMed publication ID
17679021
1 reference
stated in
Europe PubMed Central
PubMed publication ID
17679021
reference URL
https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17679021%20AND%20SRC:MED&resulttype=core&format=json
retrieved
3 January 2020
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit